14.99

1.08% 0.16

After Hours: 14.99

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $14.99, with a volume of 602.33K. It is up +1.08% in the last 24 hours and up +3.74% over the past month. WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$14.83

Open:

$14.97

24h Volume:

602.33K

Relative Volume:

0.34

Market Cap:

$2.32B

Revenue:

$113.31M

Net Income/Loss:

$-57.51M

P/E Ratio:

-11.02

EPS:

-1.36

Net Cash Flow:

$-20.55M

1W Performance:

+5.12%

1M Performance:

+3.74%

6M Performance:

+141.00%

1Y Performance:

+186.62%

1-Day Range:

$14.74

$15.32

1-Week Range:

$13.87

$15.34

52-Week Range:

$3.50

$16.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

268

Twitter

@WAVELifeSci

Next Earnings Date

2024-11-07

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	14.99	2.32B	113.31M	-57.51M	-20.55M	-1.36
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

Nov 26, 2024

Wave Life Sciences to Present at Upcoming Investor Conferences - The Manila Times

Nov 26, 2024

Nov 23, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.22 Average Price Target from Brokerages - MarketBeat

Nov 23, 2024

Nov 22, 2024

Primecap Management Co. CA Decreases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat

Nov 22, 2024

Nov 21, 2024

Insider Sale: President and CEO Paul Bolno Sells 51,234 Shares o - GuruFocus.com

Nov 17, 2024

Nov 16, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $733,670.88 in Stock - MarketBeat

Nov 16, 2024

Nov 15, 2024

Wave Life Sciences CEO Paul Bolno sells shares for $733,670 By Investing.com - Investing.com UK

Nov 15, 2024

Wave Life Sciences CEO Paul Bolno sells shares for $733,670 - Investing.com India

Nov 15, 2024

WVEWave Life Sciences Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 15, 2024

What is HC Wainwright's Forecast for WVE FY2028 Earnings? - MarketBeat

Nov 15, 2024

Wave Life Sciences to Present at Jefferies London Healthcare Conference - The Manila Times

Nov 15, 2024

What is B. Riley's Estimate for WVE Q1 Earnings? - MarketBeat

Nov 15, 2024

US$22.20That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results - Simply Wall St

Nov 15, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20 - Yahoo Finance

Nov 15, 2024

Leerink Partnrs Has Bullish Forecast for WVE FY2024 Earnings - MarketBeat

Nov 15, 2024

Nov 14, 2024

Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 14, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Short Interest Update - MarketBeat

Nov 14, 2024

Nov 13, 2024

WaVe Life Sciences's SWOT analysis: RNA editing stock faces pivotal year - Investing.com

Nov 13, 2024

Wave Life Sciences executive sells shares worth $576,000 By Investing.com - Investing.com Nigeria

Nov 13, 2024

Wave Life Sciences executive sells shares worth $576,000 - Investing.com India

Nov 13, 2024

Earnings call: Wave Life Sciences outlines transformative 2025 outlook By Investing.com - Investing.com Australia

Nov 13, 2024

Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart

Nov 13, 2024

Wave Life Sciences (NASDAQ:WVE) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 13, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Earnings call: Wave Life Sciences outlines transformative 2025 outlook - Investing.com

Nov 13, 2024